Precision Lab Pathology for Targeted Therapies
January 9, 2018 | Terry Sharrer
In the past three years, 25 new drugs have been FDA approved which target specific genetic characteristics, mainly in cancer patients. These have come from both an accelerated drug approval process, and from several gene-multiple drug companion diagnostics. As this piece concludes, “Faster approvals for these new drugs and tests will likely mean steep learning curves for pathologists. But if the streamlined regulation process being considered by the FDA works, new immunoassay tests and targeted therapies could mean improved outcomes for cancer patients.” MORE
Image Credit: LIMwiki.org